At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Closed 12-19 16:08:06
13.000
+0.370
+2.93%
High13.000Low12.290Vol5.02M
Open12.580D1 Closing12.630Amplitude5.62%
Mkt Cap12.90BTradable Cap12.90BTotal Shares992.00M
T/O64.66MT/O Rate0.51%Tradable Shares992.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Ascletis Pharma Repurchases 200,000 Shares for HKD 2.56 Million in HKEX Filing
Reuters  ·  18:22
Ascletis Pharma Repurchases 200,000 Shares for HKD 2.56 Million in HKEX Filing
Do Ascletis Pharma’s (SEHK:1672) ASC50 Phase I Results Hint At A Scalable Autoimmune Strategy?
Simply Wall St.  ·  00:14
Do Ascletis Pharma’s (SEHK:1672) ASC50 Phase I Results Hint At A Scalable Autoimmune Strategy?
HK Stock Buyback Summary | December 18
Stock News  ·  12-18 09:12
HK Stock Buyback Summary | December 18
HKEX Share Buyback Summary | December 17
Stock News  ·  12-17 09:12
HKEX Share Buyback Summary | December 17
ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$2.6099 Million on December 16
Stock News  ·  12-16
ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$2.6099 Million on December 16
Ascletis Pharma Inc. repurchases 4,586,000 shares for approximately HK$54.28 million
Reuters  ·  12-16
Ascletis Pharma Inc. repurchases 4,586,000 shares for approximately HK$54.28 million
Ascletis Pharma Inc - Ups Share Repurchase Fund to HK$500 Mln
THOMSON REUTERS  ·  12-16
Ascletis Pharma Inc - Ups Share Repurchase Fund to HK$500 Mln
ASCLETIS-B (01672) Rebounds Nearly 3% as IL-17 Inhibitor ASC50 Achieves Positive Topline Results in US Phase I Study
Stock News  ·  12-16
ASCLETIS-B (01672) Rebounds Nearly 3% as IL-17 Inhibitor ASC50 Achieves Positive Topline Results in US Phase I Study
Ascletis Pharma's Autoimmune Disease Drug Trial Shows Positive Topline Results
MT Newswires Live  ·  12-15
Ascletis Pharma's Autoimmune Disease Drug Trial Shows Positive Topline Results
Ascletis Announces Positive Topline Results From U.S. Phase I Study of Asc50, a Potential Best-in-Class Oral Small Molecule Il-17 Inhibitor
THOMSON REUTERS  ·  12-15
Ascletis Announces Positive Topline Results From U.S. Phase I Study of Asc50, a Potential Best-in-Class Oral Small Molecule Il-17 Inhibitor
Ascletis Pharma Inc - Asc50 Safe and Well Tolerated at All Dose Levels
THOMSON REUTERS  ·  12-15
Ascletis Pharma Inc - Asc50 Safe and Well Tolerated at All Dose Levels
ASCLETIS-B (01672): Positive Topline Results from US Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
Stock News  ·  12-15
ASCLETIS-B (01672): Positive Topline Results from US Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
Ascletis Pharma Reports Positive Phase I Results for Oral IL-17 Inhibitor ASC50
Reuters  ·  12-15
Ascletis Pharma Reports Positive Phase I Results for Oral IL-17 Inhibitor ASC50
Hong Kong Stocks Open Lower: Hang Seng Index Down 1%, Pharmaceutical Sector Leads Declines with ASCLETIS-B (01672) Dropping Over 5%
Stock News  ·  12-15
Hong Kong Stocks Open Lower: Hang Seng Index Down 1%, Pharmaceutical Sector Leads Declines with ASCLETIS-B (01672) Dropping Over 5%
ASCLETIS-B (01672) Repurchases 300,000 Shares for Approximately HK$4.37 Million on December 12
Stock News  ·  12-12
ASCLETIS-B (01672) Repurchases 300,000 Shares for Approximately HK$4.37 Million on December 12
Ascletis Pharma Repurchases 300,000 Shares at HK$14.8 Each, Files Disclosure with HKEX
Reuters  ·  12-12
Ascletis Pharma Repurchases 300,000 Shares at HK$14.8 Each, Files Disclosure with HKEX
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (Asc40), a First-in-Class Fasn Inhibitor for Acne Treatment
THOMSON REUTERS  ·  12-10
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (Asc40), a First-in-Class Fasn Inhibitor for Acne Treatment
ASCLETIS-B (01672): First-in-Class FASN Inhibitor Denifanstat (ASC40) NDA for Acne Treatment Accepted by China NMPA
Stock News  ·  12-10
ASCLETIS-B (01672): First-in-Class FASN Inhibitor Denifanstat (ASC40) NDA for Acne Treatment Accepted by China NMPA
China NMPA Accepts New Drug Application for Ascletis Pharma's Denifanstat for Acne Treatment
Reuters  ·  12-10
China NMPA Accepts New Drug Application for Ascletis Pharma's Denifanstat for Acne Treatment
Ascletis Pharma Inc - Nmpa Acceptance of Nda for Denifanstat
THOMSON REUTERS  ·  12-10
Ascletis Pharma Inc - Nmpa Acceptance of Nda for Denifanstat
No data available

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--